Synthetic AEDG tetrapeptide (Khavinson short-peptide bioregulator) / pineal peptide

Epitalon

CAS: 307297-39-8 MW: 390.35 g/mol Formula C14H22N4O9

Key takeaways

  • All canonical primary human-evidence publications (mortality reduction, retinopathy benefit, melatonin restoration, circadian-gene normalisation) trace to a single research network (Khavinson / SPbIBG / Korkushko, Kyiv Institute of Gerontology) 🔴; the first independent Western laboratory replication of any endpoint — the in-vitro telomere-lengthening phenotype — was published by Al-Dulaimi et al. (Brunel) in 2025, twenty-two years after the canonical Khavinson 2003 telomerase paper.
  • No FDA, EMA, MHRA, Health Canada, PMDA, NMPA, or MFDS drug approval exists; the FDA removed Epitalon (free base) and Epitalon acetate from 503A Category 2 effective 2026-04-22 and scheduled a Pharmacy Compounding Advisory Committee consultation for 2026-07-24; Russian status is dietary supplement (БАД), not medicinal product; WADA does not name Epitalon but the S0 non-approved-substances catch-all applies at all times.
  • Community Score 67 / Tier B; the "Russian Protocol" (10 mg/day subcutaneous × 10 days, twice yearly, ≥4-month washout) is the modal codified pattern; ~12 years in Western community circulation since the Evolutionary.org 2014 log; Bryan Johnson Blueprint inclusion (May 14, 2024) and Huberman Lab episodes (April 1, 2024; October 7, 2024) drove the current visibility surge.
  • Community-reported routes span three orders of magnitude (50 µg/day intranasal → 1–2 mg low-dose SC → 5–10 mg standard SC), with no human PK data to anchor any of them; the proposed unifying mechanism (sequence-specific direct binding of AEDG to histone H1.3/H1.6 and promoter-DNA motifs) lacks independent structural-biology validation (no cryo-EM, X-ray, or NMR evidence from an unaffiliated structural laboratory) and is not integrated into mainstream telomere or chromatin biology.

Two-Molecule Calibration Block

In the source literature, vendor channels, and biohacker discourse, “Epitalon” / “Epithalon” is applied to two structurally distinct preparations that share an evidentiary lineage but are not the same molecule:

  • Epithalamin (bovine pineal-gland polypeptide extract). Developed at the S.M. Kirov Military Medical Academy (Leningrad) in the 1970s–80s by V.Kh. Khavinson and V.G. Morozov; registered as a medicinal product (ЛС) within the USSR / Russian Federation pharmacopoeial framework in the 1980s–90s. The 12–15-year elderly-cohort mortality data (Korkushko 2006/2012) used Epithalamin extract, not synthetic AEDG.
  • Epitalon (synthetic Ala-Glu-Asp-Gly tetrapeptide). Designed in the 1990s by the Khavinson group as a putative active fraction of Epithalamin; CAS 307297-39-8; MW 390.35 g/mol. Circulates in Russia as a dietary supplement (БАД) under Rospotrebnadzor СГР state-registration, not as a registered medicinal product.

In-text convention used throughout this monograph: “Epitalon” refers to the synthetic AEDG tetrapeptide unless otherwise specified. Where extract-based human data are discussed (Korkushko mortality cohort, several earlier Khavinson papers), the source preparation is named explicitly as “Epithalamin extract.” The 2017 Khavinson et al. mass-spectrometric identification of endogenous AEDG within the polypeptide complex [Peer-reviewed — Khavinson 2017, Bull Exp Biol Med 164:41] 🔴 has not been independently verified; pharmacological equivalence between synthetic AEDG and the active fraction of bovine Epithalamin therefore remains an unproven premise rather than an established fact.

1. Identity

FieldValueSource
Recommended INNNone assigned — “Epitalon” is a sponsor / research designation[Academic secondary source — WHO MedNet INN database, no record]
Common name aliasesEpitalon, Epithalon, Epithalone, AEDG peptide, AEDG tetrapeptide, Khavinson tetrapeptide[Peer-reviewed — Araj 2025, Int J Mol Sci 26:2691]
CAS Registry Number307297-39-8 (free base)[Academic secondary source — PubChem CID 219042]
FDA UNIIO65P17785G[Regulatory document — FDA Substance Registration System]
Molecular formulaC₁₄H₂₂N₄O₉[Academic secondary source — PubChem CID 219042]
Molecular weight390.35 g/mol (free base)[Academic secondary source — PubChem CID 219042]
Peptide sequenceAla-Glu-Asp-Gly (AEDG)[Peer-reviewed — Khavinson 2003, Bull Exp Biol Med 135:692] 🔴
Compound classSynthetic short peptide (“Khavinson short-peptide bioregulator”); pineal tetrapeptide[Peer-reviewed — Khavinson 2020, Molecules 25:609] 🔴
OriginatorV.Kh. Khavinson, St. Petersburg Institute of Bioregulation and Gerontology (SPbIBG), Russian Federation[Peer-reviewed — Khavinson 2020, Molecules 25:609] 🔴
Russian manufacturerNPCRIZ (ООО «НПЦРИЗ») / Khavinson Peptides[Industry — NPCRIZ corporate disclosure] ⚠️ 🔴
Branded preparationsSynthetic AEDG: oral capsule / sublingual lozenge (NPCRIZ Cytomax/Cytogen line, “Endoluten Lingual,” “Epitalon Spray”). Historical: Epithalamin lyophilised IM extract (distinct preparation)[Peer-reviewed — Korkushko 2011, Bull Exp Biol Med 153:241] 🔴
Plasma half-lifeNot characterised in published peer-reviewed PK studies; expected minutes for a linear unmodified tetrapeptide by class behaviourNo primary PK source located
Oral bioavailabilityNot characterised; expected minimal absent specialised delivery (proteolysis at gastric/intestinal brush border)No primary PK source located

2. History and Development

Epitalon’s lineage begins at the S.M. Kirov Military Medical Academy in Leningrad in the 1970s, where V.Kh. Khavinson and V.G. Morozov developed a programme to isolate low-molecular-weight peptide fractions from animal tissues as putative tissue-specific “bioregulators.” Epithalamin — bovine pineal polypeptide extract — was characterised in this programme alongside Thymalin, Cortexin, Prostatilen, Retinalamin and registered as a medicinal product within the USSR / Russian Federation pharmacopoeial framework in the 1980s–90s [Peer-reviewed review — Khavinson 2002, Neuro Endocrinol Lett 23 Suppl 3:11–144] 🔴.

Through the 1990s the Khavinson group reported that the active geroprotective principle of Epithalamin could be reproduced by a synthetic tetrapeptide of composition Ala-Glu-Asp-Gly, designated Epitalon. Patents covering Epitalon and related Khavinson short peptides were filed in the Russian Federation through the early 2000s; the synthetic AEDG product entered the NPCRIZ commercial portfolio as a Rospotrebnadzor-registered dietary supplement rather than as a registered medicinal product [Industry — NPCRIZ disclosure] ⚠️ 🔴.

The canonical mechanistic paper claiming telomerase activation in cultured human somatic cells appeared in 2003 [Peer-reviewed — Khavinson 2003, Bull Exp Biol Med 135:692] 🔴. Western academic engagement remained essentially absent through the 2000s and 2010s. The first non-Russian primary investigation of Epitalon’s telomere effects published in an indexed Western journal is Al-Dulaimi et al. 2025 (Brunel University London) [Peer-reviewed — Al-Dulaimi 2025, Biogerontology 26:178; DOI 10.1007/s10522-025-10315-x; figure correction DOI 10.1007/s10522-025-10326-8 published 2025-11-15]. A collaborative Italian–Russian line at G. d’Annunzio University Chieti-Pescara (Caputi, Diomede, Trubiani, Sinjari) produced peer-reviewed work from 2019 onward; every output in that line carries Khavinson and SPbIBG co-authorship and is categorised as a Khavinson-network collaboration rather than independent replication 🔴.

3. Mechanism of Action

3.1 Demonstrated in humans

  • Increased urinary 6-sulfatoxymelatonin (6-SOMT) excretion (~1.7-fold) in middle-aged subjects with low baseline pineal output, in a small Khavinson-group cohort using synthetic AEDG [Peer-reviewed — Korkushko/Khavinson 2020, Adv Gerontol 33:865; PMID 33280326] 🔴.
  • Normalisation of circadian gene expression (CLOCK, CSNK1E, CRY2) in peripheral blood lymphocytes in the same cohort [Peer-reviewed — Khavinson 2021, Adv Gerontol 11:73] 🔴.
  • No human plasma Cₘₐₓ, AUC, t½, clearance, or oral bioavailability data located in indexed literature.

3.2 Proposed / preclinical

  • Telomerase activation / telomere lengthening. In human fetal lung fibroblasts: induction of hTERT mRNA, telomerase enzymatic activity, ~2.4-fold telomere elongation, extension of replicative capacity past the Hayflick limit [Peer-reviewed preclinical — Khavinson 2003, Bull Exp Biol Med 135:692] 🔴. Replicated in 2025 by an independent Western group at Brunel University London: Epitalon increased telomere length dose-dependently in normal HMEC / IBR.3 fibroblasts via hTERT upregulation and telomerase activity, and in BT474 / 21NT breast-cancer lines via an Alternative Lengthening of Telomeres (ALT) pathway with H1.3 / H19 derepression rather than hTERT induction [Peer-reviewed preclinical — Al-Dulaimi 2025, Biogerontology 26:178]. This is the first formal Western-laboratory replication of the mechanistic core claim.
  • Histone / chromatin binding. Molecular-modelling and in-cell work claim AEDG binds linker histones H1.3 and H1.6 at specific peptide motifs, decondensing pericentromeric heterochromatin and de-repressing age-silenced genes [Peer-reviewed preclinical — Khavinson 2003, Neuro Endocrinol Lett 24:329] 🔴; [Peer-reviewed preclinical — Khavinson 2020, Molecules 25:609] 🔴. No independent structural-biology validation (X-ray, cryo-EM, solution NMR) of sequence-specific AEDG–histone or AEDG–promoter binding from an unaffiliated structural laboratory has been published.
  • Pineal axis / melatonin. In old rhesus monkeys, intramuscular Epitalon increased nocturnal basal melatonin and normalised glucose / insulin diurnal dynamics [Peer-reviewed preclinical — Goncharova 2005, Exp Gerontol 40:51] 🔴. A separate non-Khavinson preclinical report failed to demonstrate stimulation of melatonin output by synthetic Epitalon in rats [Peer-reviewed preclinical — Djeridane 2003, J Pineal Res].
  • Anti-tumour / cancer. Reduced spontaneous mammary tumour incidence in HER-2/neu transgenic mice [Peer-reviewed preclinical — Anisimov 2002, Int J Cancer 101:7] 🔴; reduced colon carcinogenesis in DMH-treated rats [Peer-reviewed preclinical — Anisimov 2002, Cancer Lett 183:1] 🔴.
  • Retinal function. Improvement of retinal bioelectric activity in Campbell rats (congenital retinal degeneration model) [Peer-reviewed preclinical — Khavinson 2002, Neuro Endocrinol Lett 23(4):365] 🔴.
  • CNS penetration. Intranasal Epitalon altered cortical neuronal firing in rats [Peer-reviewed preclinical — Sibarov 2007, Neurosci Behav Physiol 37:889] 🔴. PEPT2-mediated BBB transit is theoretical for a tetrapeptide of this size; no transporter-binding study located.

The “short-peptide direct binding to histone and promoter-DNA motifs → gene-specific transcriptional regulation” framework that Khavinson proposes as the unifying mechanism is not mainstream molecular biology and has not been independently structurally validated. The 2025 Brunel replication validates the phenotypic endpoint (telomere lengthening in human cells) but does not validate the underlying direct-DNA-binding model.

4. Regulatory Status

4.1 Drug-regulatory status

  • FDA (United States). Not approved as a drug. Epitalon was placed in Category 2 of the FDA interim 503A Bulks List on 2023-09-29 because the Agency identified significant safety concerns (immunogenicity, impurity profile, insufficient safety data) [Regulatory document — FDA "Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks," 2023-09-29]. On 2026-04-15 the FDA published FR Doc 2026-07361, Docket FDA-2025-N-6895, removing Epitalon (free base) and Epitalon acetate from Category 2 effective 2026-04-22 and scheduling the Pharmacy Compounding Advisory Committee (PCAC) consultation on Epitalon for 2026-07-24, alongside Semax and Emideltide (DSIP) [Regulatory document — FDA PCAC meeting notice, FR Doc 2026-07361, 2026-04-15]. Removal from Category 2 does not confer Category 1 status or lawful 503A bulks-list status; it places the substance into formal scientific review. As of 2026-05-18, Epitalon remains outside any lawful 503A compounding pathway pending the July 2026 PCAC outcome.
  • EMA (European Union). Not approved. No centralised authorisation, no orphan designation, no PRIME or EMA scientific-advice record.
  • MHRA (UK). Not approved.
  • Health Canada. Not approved; no DIN; no NHP licence located.
  • PMDA (Japan). Not approved.
  • NMPA (China). Not approved.
  • MFDS (South Korea). Not approved.
  • TGA (Australia). Not listed on the Australian Register of Therapeutic Goods. Unscheduled under the Therapeutic Goods (Poisons Standard—October 2025) Instrument 2025 (SUSMP): Epitalon has no specific entry in any Schedule (S2–S10) and is not named in Appendices A–M [Regulatory document — Therapeutic Goods (Poisons Standard—October 2025) Instrument 2025, accessed 2026-05-15]. Absence from the Poisons Standard does not authorise therapeutic supply; an Epitalon product would still require ARTG registration or an authorised-access pathway (Special Access Scheme, Authorised Prescriber, Personal Importation). No ARTG entry located.
  • GRLS / Russia. Synthetic AEDG does not appear in the Russian State Register of Medicines (ГРЛС, ЛС status) as a registered pharmaceutical. It circulates in the Russian Federation as a БАД (биологически активная добавка к пище) under Rospotrebnadzor СГР state-registration for dietary supplements (TR CU 021/2011 framework), marketed primarily by NPCRIZ as oral capsules and sublingual lozenges [Regulatory framework — Rospotrebnadzor TR CU 021/2011; NPCRIZ product disclosure] ⚠️. The historical Epithalamin extract was registered as a medicinal product (ЛС) under Soviet / Russian Ministry of Health authority in the 1980s–90s but is a distinct preparation.
  • WHO Essential Medicines List. Not listed.

4.2 Anti-doping status

  • WADA 2026 Prohibited List. Not specifically named. Falls under S0 (Non-Approved Substances) — pharmacological substance with no current governmental regulatory approval for human therapeutic use, captured by the S0 catch-all [Anti-doping document — WADA 2026 Prohibited List, Section S0].
  • In-competition / Out-of-competition. S0 substances are prohibited at all times.
  • TUE eligibility. Theoretically available, practically unattainable in the absence of an approved therapeutic indication.
  • NCAA. Not separately listed; the NCAA Banned Drugs list captures unapproved peptides under “peptide hormones, growth factors, related substances and mimetics” and the catch-all “any substance that is chemically related to one of the above classes.” Athletes must assume prohibition.
  • DoD / OPSS. OPSS advises Service members that any peptide not approved by FDA for human use is high-risk; Epitalon is treated as prohibited under the same framework that captures BPC-157 and TB-500 [Anti-doping document — DoD/OPSS guidance, current as of 2026-05].
  • Global DRO. Not returned as a named entry on Global DRO checked 2026-05-15; Global DRO does not index unapproved / non-named substances; users are referred to the WADA S0 catch-all.
  • BSCG. Identifies unapproved peptides including Epitalon as S0-prohibited and high-risk for athletes [Anti-doping document — BSCG, "What's Changing With Peptide Regulation in 2026," accessed 2026-05-15].
  • Detection window. No validated detection window in published anti-doping literature. Belgian Scientific Institute of Public Health analytical work demonstrates Epitalon can be detected by HILIC-LC-MS in seized preparations [Peer-reviewed — Vanhee 2015, Drug Test Anal 7:259; Janvier 2017, Talanta 164:1].
  • Notable sanctions / precedents. No published WADA-code adjudications specifically naming Epitalon located.

4.3 Last regulatory review

Last regulatory review: 2026-05-15

5. Formulations and Routes

  • Approved formulations (Russia). Synthetic AEDG circulates as an oral capsule БАД (NPCRIZ Cytomax / Cytogen line; Endoluten-class products contain low-milligram pineal-peptide loads; specific Epitalon-only oral БАД also marketed) and as a sublingual lozenge (Endoluten Lingual, Epitalon Spray). Historical Epithalamin extract was supplied as a lyophilised injectable vial (intramuscular), dose schedule typically 5 × 10 mg IM at 3-day intervals per Korkushko protocol [Peer-reviewed — Korkushko 2007, Adv Gerontol 20:74; PMID 17426848] 🔴.
  • Clinical-study formulations. Intramuscular injection of synthetic Epitalon (5–10 mg, 5–10 day courses) in Khavinson-group cohorts; intranasal in rodent neuroactivity studies; oral capsule in the melatonin / circadian human study [Peer-reviewed — Korkushko 2020 / Khavinson 2021] 🔴.
  • Preclinical formulations. Subcutaneous, intraperitoneal, oral (drinking water) in mice, rats, fruit flies; intramuscular in rhesus monkeys.
  • Not supported by regulatory framework. Subcutaneous self-administration of grey-market reconstituted lyophilised powder — the predominant Western community route — has no regulated manufacturing, sterility, or quality framework outside the Russian БАД oral product.
  • Pharmacokinetics. No human plasma Cₘₐₓ / AUC / t½ data located. The molecule is a linear unmodified tetrapeptide with two acidic residues; oral bioavailability expected to be minimal absent specialised delivery, plasma persistence on the order of minutes expected by class behaviour. Brain penetration of intact AEDG has not been demonstrated by mass-spectrometric quantification in CNS tissue.

6. Preclinical Evidence

6a. In vitro

  • Telomerase reactivation and >40% extension of replicative lifespan in human fetal fibroblasts [Peer-reviewed preclinical — Khavinson 2003, Bull Exp Biol Med 135:692] 🔴.
  • Chromatin decondensation and ribosomal-gene activation in cultured lymphocytes from elderly donors [Peer-reviewed preclinical — Khavinson 2003, Neuro Endocrinol Lett 24:329] 🔴.
  • Neurogenic-differentiation marker upregulation (Nestin, GAP43, β-tubulin III, doublecortin) in human gingival and periodontal-ligament mesenchymal stem cells [Peer-reviewed preclinical — Caputi 2019, Int J Immunopathol Pharmacol 33:2058738419828613] 🔴 (Khavinson-network collaboration); [Peer-reviewed preclinical — Khavinson 2020, Molecules 25:609] 🔴.
  • Telomere lengthening in HMEC and IBR.3 normal cells via hTERT / telomerase, and in BT474 / 21NT cancer lines via ALT [Peer-reviewed preclinical — Al-Dulaimi 2025, Biogerontology 26:178]. First non-Khavinson Western primary replication of the telomere-length endpoint.
  • Antioxidant / anti-EMT effect in high-glucose-injured ARPE-19 retinal pigment epithelial cells [Peer-reviewed preclinical — Yin 2025, Stem Cell Rev Rep, DOI 10.1007/s12015-025-10911-x].

6b. Animal

  • ~12–16% mean-lifespan extension in Drosophila melanogaster [Peer-reviewed preclinical — Anisimov, Mylnikov, Khavinson 1998, Mech Ageing Dev 103:123] 🔴.
  • ~13% mean-lifespan extension and reduced spontaneous tumour incidence in aged female rats [Peer-reviewed preclinical — Vinogradova 2007, Bull Exp Biol Med 144:825] 🔴.
  • Reduced mammary tumour incidence and 3.7-fold reduction in HER-2/neu mRNA in HER-2/neu transgenic mice [Peer-reviewed preclinical — Anisimov 2002, Int J Cancer 101:7] 🔴.
  • Reduced colon carcinogenesis in DMH-treated rats [Peer-reviewed preclinical — Anisimov 2002, Cancer Lett 183:1] 🔴.
  • Preservation of retinal morphology and ERG activity in Campbell rats [Peer-reviewed preclinical — Khavinson 2002, Neuro Endocrinol Lett 23(4):365] 🔴.
  • Restoration of nocturnal melatonin and normalisation of glucose-insulin dynamics in aged rhesus monkeys [Peer-reviewed preclinical — Goncharova 2005, Exp Gerontol 40:51] 🔴.

6c. Independent replication status

The Brunel 2025 study (Al-Dulaimi et al.) is the first formally independent replication of the telomere-lengthening phenotype. The 2019 Caputi et al. and 2020 Khavinson / Diomede neurogenesis papers list Italian (Chieti-Pescara) authors but share SPbIBG co-authorship and are categorised as Khavinson-network collaborations rather than independent replications 🔴. No independent replication of in-vivo lifespan extension, anti-carcinogenesis, or retinal-protective effects has been published.

6d. Reproducibility limitations

A clear majority (~90%) of preclinical primary reports cited in major Epitalon reviews originate from V.Kh. Khavinson and SPbIBG / Pavlov Institute / NPCRIZ collaborators, or from the Anisimov gerontology group at the N.N. Petrov Institute (long-time Khavinson collaborator). A substantial fraction of primary data is published in Russian-language venues (Бюллетень экспериментальной биологии и медицины, Успехи геронтологии) with English translations of variable completeness. Sample-size reporting and randomisation / blinding documentation in many Khavinson-era papers do not meet contemporary ARRIVE / MIQE standards. The 2025 Araj review (Medical University of Warsaw) catalogues this dependency explicitly [Peer-reviewed — Araj 2025, Int J Mol Sci 26:2691].

7. Clinical Evidence

7a. Cochrane systematic reviews

None. A Cochrane Library search returns no systematic review of Epitalon, AEDG peptide, or Epithalamin for any indication as of 2026-05-15.

7b. Western peer-reviewed RCTs

None located meeting modern RCT standards (CONSORT-compliant design, prospective registration, allocation concealment, ITT analysis) for any indication.

7c. Khavinson-group / network human studies (primary clinical evidence) 🔴

  • Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med 2006; English 2007 (PMID 17426848). Randomised comparative study of Epithalamin extract, not synthetic Epitalon, in 79 elderly coronary patients (n=39 Epithalamin + basic therapy vs n=40 basic therapy alone); 12-year follow-up with 28% reduction in all-cause mortality and 2-fold reduction in cardiovascular mortality. Open-label; no placebo; no allocation concealment described. 🔴
  • Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector … 15-year follow-up. Bull Exp Biol Med 2012 (PMID 22451889). Extension of the same cohort to 15 years. 🔴
  • Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. Effect of peptide preparation Epithalamin on circadian rhythm … in elderly people. Bull Exp Biol Med 2004 (PMID 15452611). Epithalamin extract. 🔴
  • Khavinson VKh, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002;23(4):365–8 (PMID 12195242). Synthetic Epitalon; reports “positive clinical effect in 90% of cases” in degenerative retinal disease; design and statistical methodology not adequately specified for a controlled trial. 🔴
  • Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett 2002;23 Suppl 3:11–144 (PMID 12374906). Composite monograph summarising the Russian clinical experience. 🔴
  • Trofimova SV, Linkova NS, Klimenko AA, Kvetnaia TV, Khavinson VK. Pineamin increased pineal melatonin synthesis in elderly people. Adv Gerontol 2017 (PMID 28849889). 🔴
  • Khavinson VKh et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging. Adv Gerontol 2020 (PMID 33280326); English Adv Gerontol 11:73 (2021). 🔴

Every primary human-evidence publication located traces to V.Kh. Khavinson or O.V. Korkushko (Institute of Gerontology, Kyiv, long-time Khavinson collaborator) as senior author. No independent group has produced a peer-reviewed clinical study of Epitalon or Epithalamin in humans. 🔴

A 2024 single-patient case report combining Epitalon, Semax, and umbilical-cord MSC exosomes from a US restorative-medicine clinic exists [Peer-reviewed case report — Hutchinson 2024, Integr Med (Encinitas)] but constitutes n=1 grey-zone clinical reporting, not a controlled trial. ⚠️

7d. Russian-language reports

A substantial body of Russian-language primary clinical reports exists in Успехи геронтологии and Бюллетень экспериментальной биологии и медицины between 1996 and 2015 dealing with Epithalamin and Epitalon in coronary disease, type 2 diabetes, climacteric syndrome, and ophthalmologic indications. Western indexing is partial; full-text English translation is partial; methodological detail when available does not consistently rise to RCT standards. All identified output traces to the SPbIBG / Kyiv Institute of Gerontology network 🔴.

7e. Trial registry status

  • ClinicalTrials.gov: no registered trials of Epitalon, Epithalon, or AEDG peptide located 2026-05-18.
  • EU CTIS: no entries.
  • WHO ICTRP: no entries.
  • ClinicalTrials.ru / AIS Roszdravnadzor: no specific Epitalon trial entries located in retrievable form.

7.5 Disputed Claims

Position A — Proponents (Khavinson group and Khavinson-network collaborators). Synthetic AEDG peptide reactivates hTERT and telomerase in cultured human somatic cells, lengthens telomeres past the Hayflick limit, extends mean lifespan in rodents and fruit flies, reduces mammary and colon carcinogenesis in animal models, restores circadian melatonin in aged subjects, and reduces all-cause and cardiovascular mortality in elderly Russian-cohort follow-up. The proposed unifying mechanism is short-peptide direct binding to specific histone (H1.3 / H1.6) and promoter-DNA motifs, leading to gene-specific transcriptional regulation. Primary references: Khavinson 2003 Bull Exp Biol Med 135:692; Khavinson 2002 Neuro Endocrinol Lett 23(4):365; Korkushko 2006 / 2011 / 2012; Khavinson 2020 Molecules 25:609. 🔴 ⚠️

Position B — Mainstream telomere / chromatin biology. Independent telomerase laboratories led by the field’s senior investigators (Blackburn, Greider, Cech, Shay, Wright, Blasco, de Lange) have not engaged with the Khavinson short-peptide framework in primary publications. There is no structural-biology evidence (X-ray, cryo-EM, NMR) of sequence-specific AEDG–histone or AEDG–promoter binding from an unaffiliated structural laboratory. The 2025 Brunel study (Al-Dulaimi et al., Biogerontology 26:178) replicated the telomere-lengthening phenotype in normal human cells but interpreted the cancer-cell observation via an ALT / H1.3 mechanism distinct from — and not a positive validation of — the Khavinson “direct gene-specific transcriptional regulation by tetrapeptide” model. The maximally honest reading of the mainstream-field state is that the central mechanistic claim has not been disputed in print because the field has not engaged with it.

Disposition of dispute. Unresolved due to absence of independent replication of the human clinical claims (mortality, retinopathy, melatonin) and absence of independent structural validation of the mechanistic model. The phenotypic in-vitro telomere-lengthening endpoint received its first credible non-Khavinson replication in 2025. Twenty-three years after the canonical Khavinson 2003 telomerase paper, the absence of integration of “tetrapeptide telomerase activators” into mainstream telomere biology is itself the substantive finding.

7B. Community Evidence Layer

Community context

English-language community use traces to at least 2014, when an Evolutionary.org member began sublingual SuperNutrition / Super-Smart tablets sourced from super-smart.com. The compound passed from the steroid / PED subcommunity (IronMag Bodybuilding, MuscleChemistry, AnabolicMinds, Evolutionary.org) into the longevity / anti-aging audience proper around 2019–2021, and into the broader biohacker mainstream in 2024 after Bryan Johnson added “Epithalon & Thymulin” to the Blueprint protocol on X on 2024-05-14 and Andrew Huberman covered Epitalon on the Huberman Lab episodes of 2024-04-01 (timestamp 01:06:12) and 2024-10-07 (with Dr. Craig Koniver, timestamp 01:24:47).

Sub-community drivers in 2026, ordered by current footprint: Bryan-Johnson-adjacent longevity tech audience (post-May 2024 surge); Khavinson / Russian-peptide enclaves (oral cytomax / lingual users — rupharma.com, peptide-products.com, peptide-shop.com); concierge / longevity-clinic patients (TrufaMED, Perfect B, BodyRejuvenation, jaycampbell.com); legacy bodybuilding / PED community; r/Peptides general biohacker audience.

Popularity trajectory: rising. Healthspan (gethealthspan.com) describes Epitalon as “stirring discussion in both scientific and biohacking circles.” Rapamycin Longevity News opened a dedicated thread on the Warsaw 2025 Araj review on 2025-12-23.

Documented protocols

The Western community documents at least three named codified protocols and several route variants. Dose range spans roughly three orders of magnitude depending on route.

SourceDoseRouteCycle
Bryan Johnson, posts.bryanjohnson.com, 2024-05-1410 mg/dayIM5 days every 6 months
”Russian Protocol” (peptides.org, citing International Peptide Society 2018 monograph)10 mg/daySC10 consecutive days, up to 2×/year, ≥4-month washout (total 100 mg/course)
“Ukrainian Protocol” (peptides.org)10 mgSCDays 1, 5, 9, 13, 17 (17-day course; total 50 mg/course), up to 2×/year
Perfect B (Doral, FL clinic)10 mg nightlySC10 days, max 3 cycles/year, ≥4-month gap
Innerbody guide”5 injections per week”SC1 month on / 3 months off, 3 cycles/year
PeptideDeck / Swolverine5–10 mg/daySC or IM10–20 days, 1–2×/year
LONGECITY user “QuestforLife”10 mg QD or QODSC3 cycles over 1 year (cumulative ~100–150 mg)
forum.age-reversal.net (sublingual)3 mg sublingualSublingual lozenge (SuperNutrition)Days 1–15 of month × 4 months
The Peptide Report (intranasal)50–100 µg/dayNasal sprayCycled
Youth & Earth UK (age-tiered)1–2 mg SC or 30-day oral/sublingualSC or oral1 cycle/year at 35–45; 2 cycles at 45–70; 3 cycles at 70+

The modal codified pattern is the Russian Protocol: 10 mg/day SC × 10 days, twice yearly, ≥4-month washout. Sub-mg intranasal dosing diverges sharply from injectable protocols. Community dosing spans 50 µg → 10 mg per dose — a range of three orders of magnitude with no human PK data to anchor any of them.

Claimed effects

  • Improved sleep quality / deeper sleep within first 3–5 days of a cycle — widespread. Top sources: PeptideDeck 2026 review; Anabolic Steroid Forums log (“3rd day in…definitely a deeper sleep”); Innerbody guide; LONGECITY “QuestforLife.”
  • Vivid dreams — common. PeptideDeck 2026.
  • Melatonin / circadian-rhythm restoration — common as theoretical claim, harder to verify subjectively. Huberman Lab 2024-04-01: “can recalibrate circadian rhythm changes that occur with age.”
  • Telomere lengthening on commercial telomere tests — common claim, single-source for personal data. jaycampbell.com self-reported testimonial after 7 days at “70 units 3×/day” of a 15 mg vial: “telomere length 1.07, 83rd percentile…23 years shaved off”; LONGECITY “QuestforLife” reports Lifelength telomere tests and Zymo DNAm tests showing 2–3 years reduction over multi-year SES protocol.
  • Skin improvement (texture, smoothing, eczema / psoriasis improvement) — common. Evolutionary.org log; IronMag write-up by William Davis.
  • Improved energy / exercise recovery — common. jaycampbell.com (mile time 9:27 → 7:11); LONGECITY; Evolutionary.org.
  • Blood-sugar improvement — occasional, consistent across two named accounts. forum.age-reversal.net thread originator (“blood sugar improved dramatically”); same thread, John Mcgough confirms blood-sugar response at low MD-prescribed dose.
  • Mood / well-being / “youthfulness” — common. NuVion Health summary.
  • Reduction in neuropathic pain / decreased analgesic use — single-source. Evolutionary.org family-member log.
  • Hair growth — claimed and explicitly denied within the same review (MuscleChemistry FAQ).
  • “Nothing noticeable” — common counter-claim (see Dissent below).

Reported side effects

  • Injection-site reactions (itching, redness, swelling, mild pain) — occasional, mild. peptides.org; jaycampbell.com.
  • Insomnia paradox at high doses — occasional, moderate. forum.age-reversal.net: “I could never take these high doses as it gave me insomnia.” Notable because the canonical claim for Epitalon is improved sleep.
  • Mild fatigue / sleepiness if timing wrong — single-source occasional. PeptideDeck 2026.
  • Headache, mild nausea — single-source occasional. PeptideDeck 2026.
  • No effect / non-response — common.
  • Severe adverse events — not reported in any indexed community thread reviewed. The clean community safety record should be read against the absence of independent long-term Western pharmacovigilance.

Community dissent

  • Telomere claims skepticism. Tony Pemberton (TikTok @epicgenetics) published “Epitalon: Debunking Telomere Extension Claims.” Rapamycin Longevity News user “Tim” on the 2025-12-23 Araj review thread: “In other words, suspected fraud” — referring to methodological opacity in Khavinson’s human trials. The same thread flagged a 1000× discrepancy between effective rodent doses (~1 µg/mouse) and human biohacker doses (10 mg/day).
  • Khavinson-dependency criticism. LONGECITY user: “All of the evidence for epitalon and indeed most peptides is Russian, led by professor Khavinson.” Peptides.org itself: “much of the research involving both epithalon and epithalamin has been conducted in Russia with no independent confirmation elsewhere…we therefore encourage skepticism among researchers.”
  • Sublingual vs subcutaneous bioavailability split. forum.age-reversal.net dissenter: “the only way for Epitalon to work is through intramuscular injection…most of the sublingual would be destroyed.” PeptideDeck 2026 takes the injection side flatly: “Oral bioavailability of Epithalon is extremely low — as a tetrapeptide, it gets broken down by digestive enzymes.”
  • “Did anyone actually feel anything?” Evolutionary.org thread opener: “i am not finding any logs…just sales pitches from peptide companies”; same thread: “It’s total overplayed crap.” forum.age-reversal.net mid-experiment update: “We have not noticed any ‘effects’, either positive or negative.” Anabolic Steroid Forums log user: “2nd × 100 mg dose today. Nothing to report…Feel this pep will be a down the line type of thing.”
  • Lack of independent Western replication. Healthspan (gethealthspan.com): “Epitalon lives up to its hype mechanistically, but falls short in translational readiness. It is not ready for mainstream adoption — yet.” Rapamycin Longevity News “JuanDaw”: “Epitalon seems so promising but I don’t see enough data to warrant recommending it to people.”
  • Huberman’s hedged framing (2024-04-01) is itself widely referenced as community-level dissent against over-claiming: Shortform summary records that Epitalon’s effects “remain experimental” because there is “a notable lack of human evidence.”

Stack patterns

  • Epitalon + Thymulin (“Bryan Johnson stack”). Bryan Johnson, 2024-05-14. Framed as combined thymus rejuvenation + telomere lengthening + epigenetic age slowing.
  • Epitalon + other Khavinson bioregulators (Pinealon, Cerluten, Endoluten, Ventfort, Vladonix, Sigumir). Khavinson lingual / cytomax product lines; Youth & Earth UK recommends Pinealon + Epitalon for brain health and longevity.
  • Epitalon + NAD+ precursors (NMN/NR). Bryan Johnson Blueprint cluster. Healthspan: Epitalon fits “cleanly around continuous background therapies” like NAD+ precursors.
  • Epitalon + rapamycin. Rapamycin.news forum users routinely co-discuss. QSC vendor page bundles “NAD+, Epitalon, MOTS-c, SS-31, FOXO4-DRI, GHK-Cu, Humanin, Pinealon” as a Bryan Johnson Blueprint research cluster.
  • Epitalon + GH secretagogues (CJC-1295 / ipamorelin / sermorelin). NuVion Health summary; Excelmale TRT forum.
  • Epitalon + melatonin (oral). NuVion Health; Innerbody.
  • “SES” — statin + epitalon + sartan. LONGECITY user QuestforLife, 2018 onward.
  • Epitalon + Pinealon (REM sleep stack). Implied by Huberman / Koniver 2024-10-07 episode.

Vendor / supply context

Western research-chemical price range ~$50–$80 per 10 mg lyophilised vial; ~$150–$235 for multi-vial / wholesale 10-vial kits; sublingual lozenge bottles ~$149 for ~180 mg total active. Concierge-clinic per-cycle pricing not consistently published.

Named vendors with COA practices: Peptide Sciences (HPLC/MS COA), Biotech Peptides, Cosmic Peptides (patent-pending lot tracking, third-party COA), Northline Labs (99%+ purity, third-party), Go Alpha Labs, Pepsynth Labs, Evolve Peptides, BioLongevity Labs (three-lab verification, GMP-registered US facilities), Simple Peptide (lot-specific COA, e.g. lot EPIT10110J2025-06, 99.7%, 2026-01-23), QSC Peptides (Janoshik COA, aggressive Bryan-Johnson-Blueprint name-association marketing). Russian distribution channels: NPCRIZ / Khavinson Peptides / Garmonia Ltd via peptide-products.com, peptide-shop.com, rupharma.com, apothecarybysfraw.com; sublingual lozenges (Endoluten Lingual, Epitalon Spray). SuperNutrition / Super-Smart in the US for sublingual format. Concierge clinics: Perfect B (Doral, FL), TrufaMED, BodyRejuvenation, Pulse & Remedy.

No major brand-name scandal indexed; generic peptide-vendor consistency concerns and reconstitution-quality reports appear in Northline product reviews. Innerbody and peptides.org both flag impurity risk from non-vetted vendors. COA practice is on par with current US research-chemical-vendor norms.

Community Score / Tier

ComponentScore
Usage volume17 / 25
Protocol codification19 / 25
Reported effect consistency13 / 25
Time in circulation18 / 25
Total67 / 100 — Tier B

Pass 2 retrieval limitations (substantive disclosure preserved)

Reddit thread-level evidence (r/Peptides, r/PeptideUmbrella, r/longevity, r/Biohackers, r/Nootropics, r/SteroidsHGH, r/AntiAging) could not be retrieved at named-thread resolution in this research pass. Reddit’s mid-2023 API policy changes and the effective deprecation of Pushshift mean search engines no longer reliably surface individual Reddit threads via standard queries. No Reddit permalinks, thread titles, vote counts, or upvoted-comment text are cited in this report because they could not be verified at named-source resolution. Community sentiment is reconstructed instead from indexed forum analogs (LONGECITY, Evolutionary.org, IronMag, AnabolicMinds, MuscleChemistry, Anabolic Steroid Forums, forum.age-reversal.net, rapamycin.news, excelmale.com) and from biohacker aggregator sites that quote Reddit content second-hand without primary citation. Huberman Lab transcript verbatim quotes were sourced from third-party summaries (Podcast Notes, fastlifehacks.com, shortform.com) rather than primary transcript text. Khavinsonpeptides.com was offline (“undergoing maintenance”) during research. Per-batch COA documents from named vendors were not downloaded individually. No primary Russian-language sources retrieved (Russian Telegram, vk.com, ClinicalTrials.ru patient-cohort discussions). Discord / Telegram peptide channels not searched. Aubrey de Grey, Peter Diamandis, Rhonda Patrick, Layne Norton, David Sinclair, Siim Land — no specific named Epitalon claims confirmed; absence is non-retrieval, not evidence of non-discussion.

8. Safety Profile

  • Common AEs. Khavinson-cohort reports describe essentially no significant adverse events at study doses (5–10 mg IM, courses of 5–10 days, intermittent over years) 🔴. Adverse-event ascertainment in these reports does not meet contemporary pharmacovigilance documentation standards.
  • Class concerns. Sterile-injection practices for compounded or grey-market peptide preparations introduce sterility, endotoxin, and impurity risks independent of the active ingredient. The FDA’s 2023 Category 2 placement cited immunogenicity risk and peptide-related impurities as the basis for the significant-safety-concern designation [Regulatory document — FDA Cat 2 placement, 2023-09-29].
  • Trial exclusion criteria. Where documented in Khavinson-group cohort reports, exclusions typically include active malignancy and acute cardiovascular events; full eligibility criteria not always reported.
  • Special populations. No data in pregnancy, lactation, hepatic impairment, renal impairment, or paediatric populations.
  • Retraction check. A Retraction Watch and PubMed retraction-status search of V.Kh. Khavinson as author (executed 2026-05-15) returns no retractions of primary Epitalon / Epithalamin publications. A 2025 Biogerontology correction (DOI 10.1007/s10522-025-10326-8) replaced figures in the Al-Dulaimi 2025 paper but is a figure correction, not a retraction.
  • Long-term safety dossier. Absent in any modern pharmacovigilance sense. The 12–15-year Korkushko follow-up is the longest published human exposure record and uses Epithalamin extract not synthetic AEDG; modern adverse-event coding and signal-detection methodology were not applied. 🔴
  • Community safety signal. Injection-site reactions occasional and mild; one named insomnia-paradox report at high dose; no severe AE reports in indexed community threads. The clean community signal should be read against the absence of independent long-term Western pharmacovigilance and the structurally limited community ability to detect rare-event harms.

9. Drug Interactions

No formal pharmacokinetic or pharmacodynamic interaction studies located. Theoretical pharmacodynamic overlap with melatonin, melatonin-receptor agonists, sedative-hypnotics, and exogenous-circadian agents is plausible but unquantified. No CYP, transporter, or protein-binding data located.

10. Research Gaps

  1. Independent Western replication of the human mortality and retinopathy claims under contemporary RCT methodology.
  2. Independent structural validation (cryo-EM, X-ray, or solution NMR) of the proposed AEDG–histone H1 and AEDG–promoter direct-binding model.
  3. ICH-grade toxicology: chronic toxicity, genotoxicity, carcinogenicity, reproductive toxicology in modern regulatory format.
  4. Human pharmacokinetics: plasma Cₘₐₓ, AUC, t½, oral bioavailability of intact AEDG, demonstration of intact peptide in CNS compartment.
  5. Properly powered placebo-controlled human RCT of any defined endpoint (sleep onset / 6-SOMT excretion / retinal function in retinitis pigmentosa / cardiovascular mortality).
  6. Confirmation that synthetic AEDG is in fact pharmacologically equivalent to the active fraction of bovine Epithalamin extract (the 2017 endogenous-identification claim has not been independently verified).
  7. Mechanistic clarification of the apparent divergence in cancer-cell vs normal-cell telomere maintenance (telomerase vs ALT) reported by Al-Dulaimi 2025.
  8. Pharmacological characterisation of the route-divergent dose claims — particularly intranasal sub-mg vs subcutaneous 10 mg vs sublingual 3 mg — none of which is anchored to human PK data.

11. Bottom-Line Encyclopedia Note (≤150 words)

Epitalon is the synthetic Ala-Glu-Asp-Gly tetrapeptide developed by V.Kh. Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology, positioned within the “Khavinson short-peptide bioregulator” framework derived from the bovine pineal extract Epithalamin. The canonical evidence base — telomerase reactivation, lifespan extension in rodents, mortality reduction in elderly cohorts, retinitis-pigmentosa benefit, melatonin restoration — originates almost entirely from one research network spanning 1990s–present. Regulatory standing is limited to Russian dietary-supplement (БАД) registration; no Western drug approval exists, and FDA review under the 503A bulks-list pathway is scheduled for July 2026. The first independent Western laboratory replication of the in-vitro telomere-lengthening endpoint was published in 2025 (Brunel). Clinical human claims remain unreplicated independently. WADA does not name Epitalon but it is captured under the S0 catch-all. Reported safety in single-group cohorts is mild; long-term pharmacovigilance-quality safety data are absent.

11B. Gap Analysis

Pattern cell: Medium community + Low science → community ahead of science (medium amplitude).

The Gap Analysis matrix has four cells; Epitalon (Science C/15, Community B/67) sits in the same column as BPC-157 (D/A) and TB-500 (E/C), with the smallest amplitude of the three. The required subclassification — untested / tested-negative / tested-mixed — is tested-mixed. The in-vitro mechanistic core claim (telomere lengthening in human cells via hTERT in normal cells, via ALT in cancer cells) received its first credible independent Western replication in 2025 (Al-Dulaimi, Brunel) — twenty-two years after Khavinson 2003. The human clinical claims (mortality reduction, retinopathy benefit, melatonin restoration, circadian-gene normalisation) remain entirely single-group (Khavinson / Korkushko network 🔴) and have never been independently replicated under contemporary RCT methodology.

The specific gaps:

  1. The flagship community claim (telomere lengthening in living humans) rests on essentially no controlled human data. The mechanism is replicated in cultured fibroblasts and cancer lines. Translation to in-vivo human telomere extension is supported by no RCT. The two named community self-reports of telomere measurement (jaycampbell.com testimonial; LONGECITY “QuestforLife” multi-year Zymo / Lifelength self-tracking) are n=1 each and lack any control structure.

  2. The most consistently reported community effect (sleep improvement within 3–5 days) has zero RCT support. The mechanism (pineal axis / melatonin restoration) is plausible. The single Khavinson-group human 6-SOMT and circadian-gene study is consistent with this direction. Independent replication is absent.

  3. The proposed unifying mechanism (sequence-specific AEDG–histone / AEDG–promoter direct binding) has no independent structural-biology validation. No cryo-EM, X-ray, or solution NMR evidence from an unaffiliated structural laboratory has been published. The Brunel 2025 replication validates the phenotype; it does not validate the mechanism Khavinson proposes.

  4. Route divergence is unanchored. Community protocols span 50 µg intranasal → 1–2 mg low-dose SC → 5–10 mg standard SC → 3 mg sublingual — three orders of magnitude per dose, with no human plasma PK data to anchor any of them. Vendors and clinics treat all four routes as legitimate; no controlled head-to-head data exist.

  5. The synthetic-vs-extract equivalence premise is unverified. The Khavinson group’s 2017 mass-spec identification of endogenous AEDG within Epithalamin polypeptide complex has not been independently confirmed. The 12–15-year Korkushko mortality cohort — the only human data with a long follow-up — used Epithalamin extract, not synthetic AEDG. Whether the synthetic tetrapeptide reproduces the extract’s clinical effect remains an unverified premise. This is a real structural-evidence gap; vendor and biohacker channels routinely cite the extract data as evidence for the synthetic peptide.

  6. The “field silence” pattern is the most diagnostic feature. Independent telomere-biology laboratories (Blackburn, Greider, Cech, Shay, Wright, Blasco, de Lange) have not engaged with the Khavinson framework in primary publications. Twenty-three years after the canonical telomerase paper, mainstream telomere biology has not integrated “tetrapeptide telomerase activators” into the canon. The absence of in-print dispute reflects absence of engagement rather than positive validation.

Compared with the calibration anchors: Epitalon’s amplitude is less extreme than BPC-157 (D/A, ~78 points apart) but the structural pattern is the same — a substance the community treats as more proven than the published independent evidence supports, with the single-group dependency 🔴 the central evidentiary asterisk. Unlike BPC-157 (no in-print dispute between Sikiric and a named critic until 2025), Epitalon has a recent named-critic surfacing on the Rapamycin Longevity News forum (“Tim”: “In other words, suspected fraud” re. methodological opacity in the Russian human data, 2025-12-23) — but no peer-reviewed published critique.

12. Three Paths

Conservative path. Gates: peer-reviewed publication of pivotal placebo-controlled RCT(s) of a defined human endpoint (sleep architecture / 6-SOMT excretion / retinopathy / cardiovascular mortality); regulatory approval in ≥1 major Western jurisdiction; independent clinical replication outside the Khavinson / SPbIBG / Kyiv network; long-term outcomes data with modern pharmacovigilance coding; ICH-grade toxicology dossier. Current state meets none of these. The conservative path therefore declines the substance pending the July 2026 FDA PCAC outcome and the next decade of (or absence of) independent Western clinical work.

Moderate path. Treats Epitalon at its current Tier (Science C / Community B) with monitoring. One 10-day cycle annually at the modal “Russian Protocol” dose (10 mg/day SC × 10 days) with ≥6-month gap. Baseline panel before cycle and a follow-up panel within 4 weeks after cycle end: CBC, CMP, lipid panel, fasting insulin / glucose, HbA1c, hsCRP, fasting cortisol; for the optimisation audience already cycling, the panel piggybacks on existing bloodwork. Optional 6-SOMT urinary measurement before and after cycle for users with access. Sleep architecture monitoring via wearable (Oura, WHOOP, Eight Sleep) flags the modal community claim. Vendor selection restricted to those publishing HPLC + MS COA per batch (Peptide Sciences, Cosmic Peptides, Northline, Evolve, BioLongevity Labs, Simple Peptide, Pepsynth, BiotechPeptides, QSC). Dose ceiling: stay at 10 mg/day; do not stack to 50 mg/day per Swolverine “no greater benefit” framing. Physician dialogue open; declare to any clinician managing concurrent therapy.

High-tolerance path. Acknowledges no conservative gates are met. Multi-cycle annual schedule per Russian Protocol (2 cycles/year, 10 mg/day SC × 10 days, ≥4-month gap) or the 3-cycle Innerbody pattern (1 month on / 3 months off, 3 cycles/year). Structured methylation testing (TruDiagnostic, Zymo) and telomere length (Lifelength) pre-cycle and quarterly. Bloodwork every 3–4 months including the moderate-path panel plus IGF-1, free / total testosterone (relevant to stack interaction), HDL, ApoB. Stack co-administration possible with NAD+ precursors, rapamycin, GH secretagogues — none of these combinations has published human safety or efficacy data; the high-tolerance path accepts that. Mitigation stack: vendor with multi-lab COA verification (BioLongevity Labs, Cosmic Peptides), sterile reconstitution practice, sharps disposal protocol, structured logging. Physician monitoring strongly advised; declare to all treating clinicians given the WADA S0 status and absence of regulatory standing.

The three paths are definitions of practice, not recommendations.

13. Key References

Science layer

  1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003;135(6):692–5. 🔴
  2. Khavinson VKh, Lezhava TA, Monaselidze JR, et al. Peptide Epitalon activates chromatin at the old age. Neuro Endocrinol Lett 2003;24(5):329–33. PMID 14647006. 🔴
  3. Khavinson VKh, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett 2002;23(4):365–8. PMID 12195242. 🔴
  4. Anisimov VN, Khavinson VKh, Mylnikov SV. Pineal peptide preparation epithalamin increases the lifespan of fruit flies, mice and rats. Mech Ageing Dev 1998;103:123–32. 🔴
  5. Anisimov VN, Khavinson VKh, Provinciali M, et al. Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int J Cancer 2002;101:7–10. 🔴
  6. Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA. Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Lett 2002;183(1):1–8. 🔴
  7. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging. Bull Exp Biol Med 2006/2007. PMID 17426848. 🔴
  8. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector … 15-year follow-up. Bull Exp Biol Med 2012. PMID 22451889. 🔴
  9. Korkushko OV, Khavinson VKh, Shatilo VB, Magdich LV. Effect of peptide preparation Epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people. Bull Exp Biol Med 2004. PMID 15452611. 🔴
  10. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett 2002;23 Suppl 3:11–144. PMID 12374906. 🔴
  11. Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas in old monkeys. Exp Gerontol 2005;40(1–2):51–7. 🔴
  12. Khavinson V, Diomede F, Mironova E, et al. AEDG peptide (Epitalon) stimulates gene expression and protein synthesis during neurogenesis: possible epigenetic mechanism. Molecules 2020;25(3):609. PMID 32019204. 🔴
  13. Caputi S, Trubiani O, Sinjari B, et al. Effect of short peptides on neuronal differentiation of stem cells. Int J Immunopathol Pharmacol 2019;33:2058738419828613. PMID 30791821. 🔴
  14. Khavinson VKh, Kopylov AT, Vaskovsky BV, et al. Identification of peptide AEDG in the polypeptide complex of the pineal gland. Bull Exp Biol Med 2017;164(3):41–3. 🔴
  15. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025;26:178. DOI 10.1007/s10522-025-10315-x. First non-Khavinson Western primary replication of the telomere-lengthening endpoint.
  16. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Correction. Biogerontology 2025;27:1. DOI 10.1007/s10522-025-10326-8. PMID 41240216.
  17. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon — highly bioactive pineal tetrapeptide with promising properties. Int J Mol Sci 2025;26(6):2691. DOI 10.3390/ijms26062691.
  18. Yin et al. Epitalon in high-glucose-injured ARPE-19 cells. Stem Cell Rev Rep 2025. DOI 10.1007/s12015-025-10911-x.
  19. Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon in two illegal pharmaceutical preparations. Drug Test Anal 2015;7(3):259–64. PMID 25535022.
  20. Janvier S, et al. Analysis of illegal peptide drugs via HILIC-DAD-MS. Talanta 2017;164:1–9.
  21. PubChem CID 219042 (Epitalon, free base).
  22. FDA UNII O65P17785G.
  23. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks, Category 2 update, 2023-09-29.
  24. FDA. Pharmacy Compounding Advisory Committee; Notice of Meeting, FR Doc 2026-07361, Docket FDA-2025-N-6895, removing Epitalon from Cat 2 effective 2026-04-22; PCAC scheduled 2026-07-23/24.
  25. WADA 2026 Prohibited List, Section S0, in force 2026-01-01.
  26. Therapeutic Goods (Poisons Standard—October 2025) Instrument 2025 (Australia) — Epitalon unscheduled.
  27. Rospotrebnadzor Technical Regulation TR CU 021/2011 (БАД framework).

Community layer

  1. Bryan Johnson, posts.bryanjohnson.com. “New longevity therapy: Epithalon & Thymulin peptides.” 2024-05-14.
  2. Huberman Lab podcast — “Benefits & Risks of Peptide Therapeutics for Physical & Mental Health.” 2024-04-01.
  3. Huberman Lab podcast — “Dr. Craig Koniver: Peptide & Hormone Therapies.” 2024-10-07.
  4. peptides.org — “Epithalon Dosage Calculator and Chart” (Russian / Ukrainian Protocols).
  5. peptides.org — “Epithalon | Reviews, Clinical Trials, and Safety.”
  6. perfectb.com — “Epithalon Dosage Protocol” (Doral, FL concierge clinic).
  7. trufamed.com — “Epithalon Explained.”
  8. innerbody.com — “Epitalon Peptide | Benefits, Safety & Buying Advice [2026].”
  9. peptidedeck.com — “Epithalon Review & Where to Buy (2026).”
  10. swolverine.com — “Epitalon Dosage Guide.”
  11. youthandearth.com — “Pinealon & Epitalon: Peptides for Brain Health and Longevity.”
  12. gethealthspan.com — Dr. Herna de Wit, “Epitalon: What can this peptide do for telomere protection, aging, and longevity, and where is the evidence?”
  13. nuvion.health — “Epithalon: The Longevity Peptide.”
  14. jaycampbell.com — “Epitalon Peptide Benefits, Dosage & Side Effects.”
  15. forum.age-reversal.net — “Anti-Aging Self-Experiment with Epitalon (AEDG).”
  16. longecity.org — “Has anyone experienced age-reversal with epitalon?”
  17. evolutionary.org — “Member’s experience with Epitalon peptide” (2014-07-01).
  18. anabolicminds.com — “Epithalon/Epitalon questions.”
  19. anabolicsteroidforums.com — “Epitalon” thread.
  20. musclechemistry.com — “Epitalon review.”
  21. ironmagazineforums.com — “Epitalon 101: The ultimate anti-aging peptide” (William Davis).
  22. rapamycin.news — Araj review discussion thread, 2025-12-23.
  23. rapamycin.news — Peptides / Bioregulators thread.
  24. TikTok — @epicgenetics (Tony Pemberton), “Epitalon: Debunking Telomere Extension Claims.”
  25. Vendor pages: peptidesciences.com, biotechpeptides.com, cosmicpeptides.com, northlinelabs.org, goalphalabs.com, pepsynthlabs.com, evolvepeptides.com, biolongevitylabs.com, simplepeptide.com, qsc-usa.com.
  26. Russian distribution channels: rupharma.com, peptide-products.com, peptide-shop.com, apothecarybysfraw.com.
  27. Sublingual: super-smart.com / super-nutrition.com.

Pass 2 retrieval limitations disclosure: see Section 7B above. Reddit thread-level evidence and direct primary Russian-language sources were not retrievable at named-source resolution during the research pass.

14. Audit / Refresh Trail

  • Composed: 2026-05-18
  • Pass 1 source: epitalon_sci_2026-05-15_C15.md (last reviewed 2026-05-15)
  • Pass 2 source: epitalon_com_2026-05-16_B67_md.md (last reviewed 2026-05-16)
  • Section 4 Last regulatory review stamp: 2026-05-15
  • Two-molecule calibration block status: included; reflects Epithalamin extract vs synthetic AEDG ambiguity flagged in Pass 1. Last review of molecular-identity ambiguity: 2026-05-18.
  • Next-refresh triggers:
    • FDA PCAC outcome — scheduled 2026-07-24 (Docket FDA-2025-N-6895): refresh immediately on publication of meeting minutes / Federal Register notice.
    • Any independent Western RCT of any human endpoint of Epitalon or Epithalamin.
    • Any independent structural-biology publication of AEDG–histone or AEDG–DNA binding from an unaffiliated lab.
    • WADA Prohibited List 2027 update (effective 2027-01-01) — check for explicit Epitalon naming.
    • Any retraction of Khavinson or Al-Dulaimi 2025 primary papers.
    • TGA scheduling change (Poisons Standard updates published 6-monthly in February and October).
    • EMA, MHRA, Health Canada, PMDA, NMPA, or MFDS regulatory action.
    • Major vendor-landscape shifts: scandals, COA-failure reports, or class-wide enforcement actions against Khavinson-aligned distributors.
    • Bryan Johnson Blueprint protocol changes affecting the named Epithalon + Thymulin stack.